AJAdrianne L. Jenner

Adrianne L. Jenner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adrianne L. Jenner has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Craig Morgan

    Université de Montréal

    9 shared publications
  • Peter S. Kim

    School of Mathematics and Statistics, University of Sydney, Sydney, Australia

    8 shared publications
  • Alexander P. Browning

    School of Mathematics and Statistics University of Melbourne Australia

    7 shared publications
  • Christine E. Engeland

    Affiliation Experimental Hematology and Immunotherapy, Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Faculty of Medicine and Leipzig University Hospital, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany

    6 shared publications
  • Christopher Drovandi

    School of Mathematical Sciences Queensland University of Technology Brisbane Australia

    6 shared publications
  • Guy Ungerechts

    Affiliations Clinical Cooperation Unit “Virotherapy”, German Cancer Research Center (DKFZ), Heidelberg, Germany, National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany, Department of Medical Oncology, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany

    6 shared publications

Latest Publications

  • Open Access

    Linking Systemic Endotoxin Exposure to Retinal Microglia Migration Through Mathematical Modeling

    by Tristen M Jackson, Tyler Cassidy, Samantha J Dando, Adrianne L Jenner

    Microglia are the resident immune cells of the central nervous system (CNS), including the brain, spinal cord, and retina, where they serve as the first line of defense against infection and inflammation. Dys-regulated microglia activity has been implicated in vision-threatening diseases, highlighting the need to understand how retinal microglia respond to inflammatory stimuli. Importantly, acute inflammation induces substantial redistribution of microglia across retinal layers, yet the mechanisms governing this migration remain poorly understood. Here, we develop the first mathematical model of retinal microglia migration during inflammation to determine how inflammatory exposure, administration route, and species-specific pharmacokinetics shape redistribution dynamics across the retina. The model couples lipopolysaccharide (LPS) pharmacokinetics with microglia migration between the outer plexiform layer (OPL), inner plexiform layer (IPL), and ganglion cell layer/nerve fiber layer (GCL/NFL). Model parameters are calibrated to retinal microglia density measurements from mice following LPS (bacterial endotoxin) challenge, before extending the framework to rats and rhesus macaques to investigate species-specific responses. Simulations also compare how administration route, i.e. intravenous or intraperitoneal injections, alter retinal LPS exposure and subsequent microglia redistribution. Our results suggest that redistribution patterns are driven primarily by LPS delivery route and species-specific pharmacokinetics, rather than the initial microglia distribution across retinal layers. Together, these findings provide new insight into immune cell reorganization in the inflamed retina and demonstrate how mechanistic mathematical modeling can be adapted across experimental designs, administration routes, and animal species.

  • Open Access

    A computational investigation of pathways for ex vivo differentiation and dysfunction of healthy and patient T cells

    by M. S. Lacy, Y. Binenbaum, P. R. Buenzli, A. L. Jenner

    Adoptive T cell therapy is a promising field in cancer immunotherapy that leverages the natural ability of T cells to target and kill cancer cells. A crucial step in this therapy involves the ex vivo expansion of memory-like and effector-like T cells, but limiting their differentiation into exhaustion-associated phenotypes remains a challenge. Mathematical model-informed strategies to optimise T cell expansion may be able to exploit our understanding of T cell differentiation, but there is a large amount of uncertainty and disagreement in the biological literature regarding the ways in which T cells differentiate and become exhausted. We therefore conduct a large-scale mathematical investigation to help further our understanding of T cell differentiation during short-term ex vivo expansion. Using observations from biological literature, we first construct thousands of potential pathways connecting distinct T cell phenotypes and then formulate corresponding ordinary differential equations to test hypotheses regarding T cell differentiation and dysfunction. We fit each model to experimental data describing the ex vivo expansion of T cells originating from healthy individuals and cancer patients and accept those that most closely describe the data. From our findings, we hypothesise that cancer may alter T cell differentiation kinetics rather than the structure of the differentiation pathway, which has significant potential to inform therapeutic strategies. Our analysis proposes that T cells may not differentiate unidirectionally ex vivo ; most accepted models suggest that the cells dynamically switch between functional phenotypes. We postulate that effector-like cells may be prone to upregulating inhibitory receptors that drive exhaustion, and find that modelling effector-like proliferation is unnecessary to capture observed population dynamics. Our hypothesis-testing framework generates recommendations for promising future research avenues and may pave the way to improve the production of patient-tailored T cell populations for adoptive cell therapy. Author summary: T cells are immune cells that are capable of detecting and killing cancer cells, however, they are often unable to control tumour growth. Most adoptive cell therapies consider treating cancers by growing T cell populations in culture dishes outside the body and re-infusing these cells into cancer patients. T cells may be found in many unique states with varying utility in adoptive cell therapy, but it is not well understood how they transition between these states during cell culture. We propose a computational method that has the capability to address this issue. We first construct thousands of literature-informed mathematical model variations that describe the growth of relevant T cell subpopulations and compare their solutions to biological experiments. Selecting the models that best match the data, we propose hypotheses regarding characteristic pathways that connect these states, which may help to improve the production of desired T cell subtypes. Our findings also indicate that T cells may follow the same pathway to transition between states regardless of whether they originate from healthy individuals or from cancer patients. Our method may lead to computer-based optimisation strategies that could determine patient-specific culture conditions that improve adoptive cell therapy for treating cancer.

  • Open Access

    In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol

    by Adrianne L. Jenner, Robyn P. Araujo, Noa L. Levi, Guy Ungerechts, Christine E. Engeland, Johannes P. W. Heidbuechel

    Immunotherapies have become a transformative therapeutic strategy for many cancer types in recent years. Bispecific T-cell engagers (BiTEs) are one promising immunotherapy that enhances cellular antitumour immunity by redirecting T cells towards cancer cells. Recent evidence suggests that BiTE efficacy can be augmented by encoding BiTEs in oncolytic measles virus vectors (MV-BiTE). Infection of cancer cells with MV-BiTE causes the local production of BiTEs and has shown safety and efficacy in murine tumour models. However, whether the observed efficacy of this treatment will translate to a heterogeneous human population is unknown. In this work, we generate an in silico clinical trial of MV-BiTE therapy using a system of ordinary differential equations. We capture potential heterogeneity of individual patients using variability in in vivo tumour volume and change in baseline (%) measurements from a Phase II clinical trial. In lieu of human MV-BiTE data, we use the oncolytic virus talimogene laherparepvec (T-VEC) as a surrogate oncolytic virus carrying an immunostimulatory payload. Our predictions imply that the main drivers of heterogeneity are the underlying effector T cell killing rate and BiTE pharmacokinetics. Furthermore, we find that if individuals are classified as non-responders to the Phase II T-VEC clinical protocol, they may respond to more frequent administration of lower dosages. This work highlights how in silico clinical trials can provide predictions for novel therapeutics to generate hypotheses and guide the design of treatment schedules for clinical translation.

  • Open Access

    A mathematical model for inflammation and demyelination in multiple sclerosis

    by Adrianne Jenner, Georgia Weatherley, Federico Frascoli

    Multiple sclerosis (MS) is an incurable, life-long disease caused by the demyelination of neurons in the brain and spine. MS is often characterized by relapses in inflammation and demyelination, followed by periods of remission. Symptoms can be highly debilitating, and there are still many open questions about the origin and progression of the disease. Mathematical modelling is well placed to capture the dynamics of MS and provide insight into disease aetiology. In this work, we present a minimal model for MS disease onset and progression driven by inflammation and demyelination. The model dynamics are capable of describing a typical evolution of the illness, with changes from a healthy state to a diseased scenario captured by certain ranges of parameter values. Our model also describes the non-uniform oscillatory nature of the disease, born from a Hopf bifurcation owing to the strength of the inflammatory response. In particular, using experimental data for contrast-enhancing lesions obtained from MS patients, we can reproduce some of the typical relapsing–remitting behaviours of this disease. We hope that the model presented here can serve as a baseline for more complex approaches and as a tool for predicting possible evolutions of the disease.


  • Open Access

    In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol

    by Adrianne L. Jenner, Robyn P. Araujo, Noa L. Levi, Guy Ungerechts, Christine E. Engeland, Johannes P.W. Heidbuechel

    Immunotherapies have become a transformative therapeutic strategy for many cancer types in recent years. Bispecific T-cell engagers (BiTEs) are one promising immunotherapy that enhances cellular antitumour immunity by redirecting T cells towards cancer cells. Recent evidence suggests that BiTE efficacy can be augmented by encoding BiTEs in oncolytic measles virus vectors (MV-BiTE). Infection of cancer cells with MV-BiTE causes the local production of BiTEs and has shown safety and efficacy in murine tumour models. However, whether the observed efficacy of this treatment will translate to a heterogeneous human population is unknown. In this work, we generate an in silico clinical trial of MV-BiTE therapy using a system of ordinary differential equations. We capture potential heterogeneity of individual patients using variability in in vivo tumour volume and change in baseline (%) measurements from a Phase II clinical trial. In lieu of human MV-BiTE data, we use the oncolytic virus talimogene laherparepvec (T-VEC) as a surrogate oncolytic virus carrying an immunostimulatory payload. Our predictions imply that the main drivers of heterogeneity are the underlying effector T cell killing rate and BiTE pharmacokinetics. Furthermore, we find that if individuals are classified as non-responders to the Phase II T-VEC clinical protocol, they may respond to more frequent administration of lower dosages. This work highlights how in silico clinical trials can provide predictions for novel therapeutics to generate hypotheses and guide the design of treatment schedules for clinical translation. Author summary: The immune system has the ability to kill cancer cells; however, cancer cells are able to resist immune cell-mediated killing. A new therapy uses modified measles viruses to activate the immune system against cancer. These viruses are modified with bispecific T-cell engagers (BiTEs) which assist immune cells in targeting and removing cancer cells. While the potential success of this treatment has been demonstrated in mouse models, it is yet to be verified in a human cohort. In this work, we use mathematical and computational simulations to examine how patient-to-patient variability might affect the success of this treatment. We compare our model predictions to data from a clinical trial and find that virtual individuals in the simulation that are classified as non-responders to the standard protocol would likely respond better to more frequent administrations of lower dosages. The work presented here generates hypotheses for how individuals in a human cohort may respond, however, more work is required to verify these results in humans.

  • Open Access

    A stochastic model of T cell expansion in micro-rod scaffolds and its continuum limit: importance of IL-2 loading and scaffold structure

    by Mason S. Lacy, Adrianne L. Jenner, Pascal R. Buenzli

    T cells are immune cells that are known to be effective at fighting cancer. However, tumour-specific T cell counts are often insufficient to control cancer growths. Adoptive T cell therapy aims to leverage the cancer-killing functions of the immune system by activating and expanding highly effective T cells ex vivo before injecting them into a cancer patient. Recent experimental setups in which T cells are cultured within activating micro-rod scaffolds have achieved significantly improved yields compared with previous methods. There is still much to understand regarding the factors that maximize the expansion of T cells in these scaffolds. In this paper, we present a stochastic agent-based model of T cell expansion alongside its continuum limit to simulate the average interactions between T cells and micro-rods. Our numerical simulations demonstrate that expansion is driven by activated T cells concentrated around micro-rods. Activation is initially fastest in scaffolds with homogeneous micro-rod concentrations, and our results suggest that rapid expansion could be further supported by the gradual movement of micro-rods and cells into heterogeneous clusters. Our simulations reveal that loading the T cell growth factor interleukin-2 into micro-rods significantly prolongs expansion compared with the conventional method of supplementing interleukin-2 into the culture medium.


  • Open Access

    A hybrid discrete-continuum modelling approach for the interactions of the immune system with oncolytic viral infections

    by David Morselli, Marcello E. Delitala, Adrianne L. Jenner, Federico Frascoli


  • Investigating the impact of macrophage lineage on atherosclerotic plaque development using an agent-based model

    by Adrianne L. Jenner, Angela M. Reynolds, Keith L. Chambers, Andrew J. Murphy, Helen M. Byrne, Mary R. Myerscough

  • Open Access

    Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis

    by Georgia R. Weatherley, Robyn P. Araujo, Samantha J. Dando, Adrianne L. Jenner

    Multiple sclerosis (MS) is a neurodegenerative disease in which misdirected, persistent activity of the immune system degrades the protective myelin sheaths of nerve axons. Historically, treatment of MS has relied on disease-modifying therapies that involve immunosuppression, such as targeting of the blood-brain barrier (BBB) to restrict lymphocyte movement. New therapeutic ideas in the development pipeline are instead designed to promote populations of myelin producing cells, oligodendrocytes, by exploiting their innate resilience to the stressors of MS or restoring their numbers. Given the significant advancements made in immunological disease understanding due to mathematical and computational modelling, we sought to develop a platform to (1) interrogate our understanding of the neuroimmunological mechanisms driving MS development and (2) examine the impact of different therapeutic strategies. To this end we propose a novel, open-source, agent-based model of lesion development in the CNS. Our model includes crucial populations of T cells, perivascular macrophages, and oligodendrocytes. We examine the sensitivity of the model to key parameters related to disease targets and conclude that lesion stabilisation can be achieved when targeting the integrated stress response of oligodendrocytes. Most significantly, complete prevention of lesion formation is observed when a combination of approved BBB-permeability targeting therapies and integrated-stress response targeting therapies is administered, suggesting the potential to strike a balance between a patient’s immune inflammation and their reparative capacity. Given that there are many open questions surrounding the etiology and treatment of MS, we hope that this malleable platform serves as a tool for experimentalists and modellers to test and generate further hypotheses regarding this disease. Multiple sclerosis is a disease that is not yet fully understood and has no cure. Some patient phenotypes see little benefit from current therapeutic interventions besides symptomatic treatment. Typically, MS studies have focused on the prevention of damage to brain tissue. As such, there are unanswered questions about how to reverse the damage in the brain and spinal cord of MS patients caused by immune cells. In light of this there is an urgent need for mathematical modelling of new therapeutic strategies - some of which remain to be clinically examined - shifting the attention from the targeting of aberrant immune activity to the upregulation of resident, reparative cells called oligodendrocytes. Here, we have developed a mathematical model to probe the potential benefits of oligodendrocyte targeted therapies in silico. We focus on T cells as damaging agents and monitor oligodendrocyte function in response to their activity. We show that oligodendrocytes strongly influence the tissue’s ability to stabilise and even recover under persistent, harmful immune activity. In practice, these therapies could hold the potential to unlock neuroprotection by means of enhanced remyelination.


  • Open Access

    A New Paradigm for the Mathematical Modelling of Multiple Sclerosis

    by Thomas Hillen, Adrianne L Jenner

    Multiple Sclerosis (MS) is an autoimmune diseases that affects the central nervous system. It can lead to inflammation, neurodegeneration, and physical or cognitive disability. Currently, no cure for MS exists, but medications are available to slow its progression. To date, mathematical modelling of MS has focussed on a few aspects of the disease, but an overall modelling framework is missing. In this paper, we propose a new paradigm for the mathematical modelling of MS. Based on biological principles, we propose six consecutive modelling levels and develop the first three model levels in this work using systems of ordinary differential equations. We test if these models can describe known effects related to MS disease risk, with particular focus on estrogen, vitamin D, Epstein-Barr virus (EBV) and HLA-DR mutations. We first show that periodic disease outbreaks are possible in this framework through interactions by antigen-presenting cells, regulatory cells and memory B cells. We show that the presence of Epstein-Barr virus infections can initiate the disease, low and high levels of estrogen and vitamin D deficiency can alleviate it, mutations in the HLA-DR gene can promote MS, and we find that memory B-cells play a dominant role in the disease progression. We hope that this framework may serve as a reference for the development and comparative evaluation of future mathematical and computational models of MS.